SEC Form 4 · accession 0001179110-16-029002
BeOne Medicines Ltd. · ONC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy C. Peterson
Officer — CMO, Immuno-oncology
Period of report
Aug 22, 2016
Accepted (ET)
Aug 24, 2016 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651308
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 22, 2016 | A | 300,000 | $0.00 | A | 300,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $2.24 | Aug 22, 2016 | A | 1,600,000 | A | — | Aug 21, 2026 | Ordinary Shares | 1,600,000 | 1,600,000 | D |
Explanation of responses
- F1These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.